首页 / 产品 / 抗体 / 一抗

Mouse Monoclonal PLAU Antibody

  • 中文名: PLAU抗体
  • 别    名: ATF; QPD; UPA; URK; u-PA; BDPLT5
货号: IPD32276
Price: ¥1280
数量:
大包装询价

验证与应用

应用及物种
WB 咨询技术 Human,Mouse,Rat
IF 咨询技术 Human,Mouse,Rat
IHC 咨询技术 Human,Mouse,Rat
ICC 技术咨询 Human,Mouse,Rat
FCM 1/200 - 1/400 Human,Mouse,Rat
Elisa 1/10000 Human,Mouse,Rat

产品详情

AliasesATF; QPD; UPA; URK; u-PA; BDPLT5
Entrez GeneID5328
clone6A7C6
WB Predicted band size48.5KDa
Host/IsotypeMouse IgG1
Antibody TypePrimary antibody
StorageStore at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles.
Species ReactivityHuman
ImmunogenPurified recombinant fragment of human PLAU (AA: 107-379) expressed in E. Coli.
FormulationPurified antibody in PBS with 0.05% sodium azide

+ +

参考文献

以下是3篇关于PLAU(uPA)抗体的代表性文献,按研究领域分类列举:

---

1. **文献名称**:*The role of urokinase-type plasminogen activator (uPA) in cancer metastasis*

**作者**:Andreasen PA et al.

**摘要**:该研究综述了uPA在肿瘤侵袭和转移中的作用,强调其通过激活纤溶酶降解细胞外基质的机制,并讨论了针对uPA/uPAR系统的抗体在抑制转移中的潜在治疗价值。

---

2. **文献名称**:*Development of a monoclonal antibody targeting the catalytic domain of urokinase plasminogen activator (uPA) for cancer therapy*

**作者**:Mazzieri R et al.

**摘要**:研究团队开发了一种靶向uPA催化结构域的单克隆抗体,体外实验显示其能有效抑制uPA活性,并在小鼠模型中减少乳腺癌细胞的肺转移,证明其作为治疗性抗体的潜力。

---

3. **文献名称**:*uPA as a prognostic marker in colorectal cancer: Validation of an immunohistochemical antibody assay*

**作者**:Beyer BC et al.

**摘要**:该研究验证了一种用于结直肠癌组织uPA检测的抗体免疫组化方法,发现uPA高表达与患者预后不良显著相关,提示其作为临床生物标志物的可行性。

---

注:以上文献为示例性质,实际引用时建议通过PubMed或Web of Science以“PLAU antibody”或“uPA therapeutic”等关键词检索最新研究。

背景信息

The plasminogen activator, urokinase (PLAU), also known as uPA, is a serine protease encoded by the PLAU gene. It plays a critical role in extracellular matrix (ECM) degradation by converting plasminogen to plasmin, a broad-spectrum protease. uPA is anchored to the cell surface via its receptor (uPAR), forming a system that regulates cell migration, tissue remodeling, and fibrinolysis. Dysregulation of uPA is implicated in pathological processes, including cancer metastasis, chronic fibrosis, and inflammatory diseases. In oncology, elevated uPA expression correlates with tumor invasion, angiogenesis, and poor prognosis in breast, colorectal, and ovarian cancers.

PLAU antibodies are tools designed to target uPA for therapeutic or diagnostic purposes. Therapeutically, they inhibit uPA’s proteolytic activity or disrupt uPA-uPAR interactions, thereby blocking ECM degradation and cancer spread. Some monoclonal antibodies (e.g., ATN-291) have shown preclinical efficacy in reducing tumor growth. Diagnostically, PLAU antibodies are used in ELISA, immunohistochemistry, or imaging to quantify uPA levels in tissues or serum, aiding cancer staging or treatment monitoring. Challenges include optimizing specificity and delivery, but ongoing research explores conjugates (e.g., antibody-drug) and combinatorial therapies. PLAU antibodies thus represent a promising avenue for precision medicine in oncology and fibrotic disorders.

客户数据及评论

折叠内容

大包装询价

×